A Single-Center Retrospective Study to Investigate the Follow-Up of Patients with Monoclonal Proteinemia by Community Physicians in the UK

References

• Available from: http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/myeloma/incidence#ref-0. Accessed 520, 2020.
   Google Scholar
• Weiss BM, Abadie J, Verma P, Howard RS, Kuehl WM. A monoclonal gammopathy precedes multiple myeloma in most patients. Blood. 2009;113(22):5418–5422. doi:10.1182/blood-2008-12-19500819234139
   PubMed Web of Science ®Google Scholar
• Landgren O, Kyle RA, Pfeiffer RM, et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood. 2009;113:5412–5417. doi:10.1182/blood-2008-12-19424119179464
   PubMed Web of Science ®Google Scholar
• Kyle RA, Rajkumar SV. Monoclonal gammopathy of undetermined significance and multiple myeloma. JAMA Oncol. 2015;1:174–175. doi:10.1001/jamaoncol.2015.3326181018
   PubMed Web of Science ®Google Scholar
• Wadhera RK, Rajkumar SV. Prevalence of monoclonal gammopathy of undetermined significance: a systematic review. Mayo Clin Proc. 2010;85:933–942. doi:10.4065/mcp.2010.033720713974
   PubMed Web of Science ®Google Scholar
• Kyle RA, Therneau TM, Rajkumar SV, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med. 2006;354:1362–1369. doi:10.1056/NEJMoa05449416571879
   PubMed Web of Science ®Google Scholar
• Melton LJ, Rajkumar SV, Khosla S, Achenbach SJ, Oberg AL, Kyle RA. Fracture risk in monoclonal gammopathy of undetermined significance. J Bone Miner Res. 2004;19:25–30. doi:10.1359/jbmr.030121214753733
   PubMed Web of Science ®Google Scholar
• Piot JM, Royer M, Schmidt-Tanguy A, et al. Factors associated with an increased risk of vertebral fracture in monoclonal gammopathies of undetermined significance. Blood Cancer J. 2015;5:e345. doi:10.1038/bcj.2015.7126314987
   PubMed Web of Science ®Google Scholar
• Kristinsson SY, Tang M, Pfeiffer RM, et al. Monoclonal gammopathy of undetermined significance and risk of skeletal fractures: a population-based study. Blood. 2010;116:2651–2655. doi:10.1182/blood-2010-04-28284820610813
   PubMed Web of Science ®Google Scholar
• Veronese N, Luchini C, Solmi M, Sergi G, Manzato E, Stubbs B. Monoclonal gammopathy of undetermined significance and bone health outcomes: a systematic review and exploratory meta-analysis. J Bone Miner Metab. 2018;36:128–132. doi:10.1007/s00774-017-0817-828243796
   PubMed Web of Science ®Google Scholar
• Kristinsson SY, Pfeiffer RM, Björkholm M, et al. Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study. Blood. 2010;115:4991–4998. doi:10.1182/blood-2009-11-25207220299513
   PubMed Web of Science ®Google Scholar
• Gregersen H, Nørgaard M, Severinsen MT, Engebjerg MC, Jensen P, Sørensen HT. Monoclonal gammopathy of undetermined significance and risk of venous thromboembolism. Eur J Haematol. 2011;86:129–134. doi:10.1111/j.1600-0609.2010.01539.x20942842
   PubMed Web of Science ®Google Scholar
• Ludwig H, Delforge M. Threatening clots in MGUS and myeloma. Blood. 2010;115:4975–4976. doi:10.1182/blood-2010-04-27634520558621
   PubMed Web of Science ®Google Scholar
• Rosner MH, Edeani A, Yanagita M, Glezerman IG, Leung N; American Society of Nephrology Onco-Nephrology Forum. Paraprotein-related kidney disease: diagnosing and treating monoclonal gammopathy of renal significance. Clin J Am Soc Nephrol. 2016;11:2280–2287. doi:10.2215/CJN.0292031627526705
   PubMed Web of Science ®Google Scholar
• Chaudhry HM, Mauermann ML, Rajkumar SV. Monoclonal gammopathy–associated peripheral neuropathy: diagnosis and management. Mayo Clin Proc. 2017;92(5):838–850. doi:10.1016/j.mayocp.2017.02.00328473042
   PubMed Web of Science ®Google Scholar
• Fermand J-P, Bridoux F, Dispenzieri A, et al. Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications. Blood. 2018;132(14):1478–1485. doi:10.1182/blood-2018-04-83948030012636
   PubMed Web of Science ®Google Scholar
• Berenson JR, Yellin O, Quiery A, et al. A retrospective study to evaluate the work-up and follow-up of patients with monoclonal gammopathy of undetermined significance. Clin Lymphoma Myeloma Leuk. 2011;11:336–341. doi:10.1016/j.clml.2011.02.00221816371
   PubMed Web of Science ®Google Scholar
• Bird J, Behrens J, Westin J, et al. Haemato-oncology Task Force of the British Committee for Standards in Haematology, UK Myeloma Forum and Nordic Myeloma Study Group. UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS). Br J Haematol. 2009;147:22–42. doi:10.1111/j.1365-2141.2009.07807.x19673884
   PubMed Web of Science ®Google Scholar
• Adams RA, Smith L, Pickering PE. The incidence of monoclonal proteins during 7 years of screening in a district general hospital. Immunology. 1984;51:451.6698575
   PubMed Web of Science ®Google Scholar
• Go RS, Heien HC, Sangaralingham LR, Habermann EB, Shah ND. Risk of progression of monoclonal gammopathy of undetermined significance into lymphoplasmacytic malignancies: determining demographic differences in the USA. Haematologica. 2018;103(3):e123–e125. doi:10.3324/haematol.2017.17997829269527
   PubMed Web of Science ®Google Scholar
• Twycross A, Shorten A. Service evaluation, audit and research: what is the difference? Evid Based Nurs. 2014;17:65–66. doi:10.1136/eb-2014-10187124829302
   PubMedGoogle Scholar
• Available from: https://www.england.nhs.uk/wp-content/uploads/2019/10/data-protection-policy-v5.1.pdf. Accessed 520, 2020.
   Google Scholar
• Therneau TM, Kyle RA, Melton LJ 3rd, et al. Incidence of monoclonal gammopathy of undetermined significance and estimation of duration before first clinical recognition. Mayo Clin Proc. 2012;87(11):1071–1079. doi:10.1016/j.mayocp.2012.06.01422883742
   PubMed Web of Science ®Google Scholar
• Kyle RA, Durie BG, Rajkumar SV, et al.; International Myeloma Working Group. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia. 2010;24(6):1121–1127. doi:10.1038/leu.2010.6020410922
   PubMed Web of Science ®Google Scholar
• Saleun JP, Vicariot M, Deroff P, Morin JF. Monoclonal gammopathies in the adult population of Finistère, France. J Clin Pathol. 1982;35:63–66. doi:10.1136/jcp.35.1.636801095
   PubMed Web of Science ®Google Scholar
• Kyle RA, Larson DR, Therneau TM, et al. Long-term follow-up of monoclonal gammopathy of undetermined significance. N Engl J Med. 2018;378(3):241–249. doi:10.1056/NEJMoa170997429342381
   PubMed Web of Science ®Google Scholar
• Turesson I, Kovalchik SA, Pfeiffer RM, et al. Monoclonal gammopathy of undetermined significance and risk of lymphoid and myeloid malignancies: 728 cases followed up to 30 years in Sweden. Blood. 2014;123:338–345. doi:10.1182/blood-2013-05-50548724222331
   PubMed Web of Science ®Google Scholar
• Eisele L, Dürig J, Hüttmann A, et al.; Heinz Nixdorf Recall Study Investigative Group. Prevalence and progression of monoclonal gammopathy of undetermined significance and light-chain MGUS in Germany. Ann Hematol. 2012;91:243–248. doi:10.1007/s00277-011-1293-121789623
   PubMed Web of Science ®Google Scholar
• van de Poel MH, Coebergh JW, Hillen HF. Malignant transformation of monoclonal gammopathy of undetermined significance among out-patients of a community hospital in southeastern Netherlands. Br J Haematol. 1995;91:121–125. doi:10.1111/j.1365-2141.1995.tb05256.x7577618
   PubMed Web of Science ®Google Scholar
• Baldini L, Guffanti A, Cesana BM, et al. Role of different hematologic variables in defining the risk of malignant transformation in monoclonal gammopathy. Blood. 1996;87:912–918. doi:10.1182/blood.V87.3.912.bloodjournal8739128562962
   PubMed Web of Science ®Google Scholar
• Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Melton LJ 3rd. Long-term follow-up of 241 patients with monoclonal gammopathy of undetermined significance: the original mayo clinic series 25 years later. Mayo Clin Proc. 2004;79:859–866. doi:10.4065/79.7.85915244381
   PubMed Web of Science ®Google Scholar
• Schaar CG, Cessie S, Snijder S, et al. Long-term follow-up of a population based cohort with monoclonal proteinaemia. Br J Haematol. 2009;144(2):176–184. doi:10.1111/j.1365-2141.2008.07423.x19036113
   PubMed Web of Science ®Google Scholar
• Cesana C, Klersy C, Barbarano L, et al. Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. J Clin Oncol. 2002;20:1625–1634. doi:10.1200/JCO.2002.20.6.162511896113
   PubMed Web of Science ®Google Scholar
• Pérez-Persona E, Vidriales MB, Mateo G, et al. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood. 2007;110:2586–2592. doi:10.1182/blood-2007-05-08844317576818
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Kyle RA, Therneau TM, et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood. 2005;106:812–817. doi:10.1182/blood-2005-03-103815855274
   PubMed Web of Science ®Google Scholar
• Steingrímsson V, Lund SH, Turesson I, et al. Population-based study on the impact of the familial form of waldenström macroglobulinemia on overall survival. Blood. 2015;125:2174–2175. doi:10.1182/blood-2015-01-62206825814489
   PubMed Web of Science ®Google Scholar
• Gregersen H, Mellemkjaer L, Ibsen JS, Dahlerup JF, Thomassen L, Sørensen HT. The impact of M-component type and immunoglobulin concentration on the risk of malignant transformation in patients with monoclonal gammopathy of undetermined significance. Haematologica. 2001;86(11):1172–1179.11694403
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Katzmann JA, Kyle RA, et al. Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. Lancet. 2010;375:1721–1728. doi:10.1016/S0140-6736(10)60482-520472173
   PubMed Web of Science ®Google Scholar
• Landgren O, Graubard BI, Katzmann JA, et al. Racial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12,482 persons from the National Health and Nutritional Examination Survey. Leukemia. 2014;28:1537–1542. doi:10.1038/leu.2014.3424441287
   PubMed Web of Science ®Google Scholar
• Sigurdardottir EE, Turesson I, Lund SH, et al. The role of diagnosis and clinical follow-up of monoclonal gammopathy of undetermined significance on survival in multiple myeloma. JAMA Oncol. 2015;1:168–174. doi:10.1001/jamaoncol.2015.2326181017
   PubMed Web of Science ®Google Scholar
• Go RS, Gundrum JD, Neuner JM. Determining the clinical significance of monoclonal gammopathy of undetermined significance: a SEER-medicare population analysis. Clin Lymphoma Myeloma Leuk. 2015;15:177–186. doi:10.1016/j.clml.2014.09.00425445471
   PubMed Web of Science ®Google Scholar
• Bianchi G, Kyle RA, Colby CL, et al. Impact of optimal follow-up of monoclonal gammopathy of undetermined significance on early diagnosis and prevention of myeloma-related complications. Blood. 2010;116:2019–2025. doi:10.1182/blood-2010-04-27756620495076
   PubMed Web of Science ®Google Scholar
• Anagnostopoulos A, Evangelopoulou A, Sotou D, Gika D, Mitsibounas D, Dimopoulos MA. Incidence and evolution of monoclonal gammopathy of undetermined significance (MGUS) in Greece. Ann Hematol. 2002;81(7):357–361. doi:10.1007/s00277-002-0493-012185503
   PubMed Web of Science ®Google Scholar
• Go RS, Swanson KM, Sangaralingham LR, Habermann EB, Shah ND. Clinical prevalence (diagnosed cases) of monoclonal gammopathy of undetermined significance in the US: estimating the burden on health care. Leukemia. 2016;30:1443–1446. doi:10.1038/leu.2015.33626648533
   PubMed Web of Science ®Google Scholar
• Go RS, Heien HC, Sangaralingham LR, Habermann EB, Shah ND. Monoclonal gammopathy of undetermined significance: follow-up patterns in the united states and concordance with clinical practice guidelines. Mayo Clin Proc Innov Qual Outcomes. 2017;1:161–169. doi:10.1016/j.mayocpiqo.2017.06.00230225412
   PubMedGoogle Scholar
• Go RS, Doyle LM. A monoclonal gammopathy in search of clinical significance: 57 years later. Blood. 2009;114:2355–2356. doi:10.1182/blood-2009-06-22912019745077
   PubMed Web of Science ®Google Scholar